Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
Top Cited Papers
Open Access
- 1 March 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Infectious Diseases and Therapy
- Vol. 9 (1), 17-40
- https://doi.org/10.1007/s40121-020-00286-6
Abstract
Cefiderocol, formerly S-649266, is a first in its class, an injectable siderophore cephalosporin that combines a catechol-type siderophore and cephalosporin core with side chains similar to cefepime and ceftazidime. This structure and its unique mechanism of action confer enhanced stability against hydrolysis by many beta-lactamases, including extended spectrum beta-lactamases such as CTX-M, and carbapenemases such as KPC, NDM, VIM, IMP, OXA-23, OXA-48-like, OXA-51-like and OXA-58. Cefiderocol's spectrum of activity encompasses both lactose-fermenting and non-fermenting Gram-negative pathogens, including carbapenem-resistant Enterobacterales. Cefiderocol recently received US Food and Drug Administration approval for the treatment of complicated urinary tract infections, including pyelonephritis, and is currently being evaluated in phase III trials for nosocomial pneumonia and infections caused by carbapenem-resistant Gram-negative pathogens. The purpose of this article is to review existing data on the mechanism of action, microbiology, pharmacokinetics, pharmacodynamics, efficacy, and safety of cefiderocol to assist clinicians in determining its place in therapy.This publication has 44 references indexed in Scilit:
- Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal FunctionAntimicrobial Agents and Chemotherapy, 2017
- Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2016
- Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal ImpairmentThe Journal of Clinical Pharmacology, 2016
- Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant CarbapenemasesAntimicrobial Agents and Chemotherapy, 2016
- Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated EfficacyAntimicrobial Agents and Chemotherapy, 2015
- Mechanisms of antimicrobial resistance in Gram-negative bacilliAnnals of Intensive Care, 2015
- Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsOpen Forum Infectious Diseases, 2015
- Iron in Infection and ImmunityCell Host & Microbe, 2013
- Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2009
- Identification of Acinetobacter baumannii by Detection of the bla OXA-51-like Carbapenemase Gene Intrinsic to This SpeciesJournal of Clinical Microbiology, 2006